SCHEMBL8146154

SCHEMBL8146154

Cc1nc2cc(NC(=S)Nc3ccccc3)ccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
ALDH1A1 P00352 4/20 0.55
MAOA P21397 2/20 0.55
MAOB P27338 2/20 0.55
GAA P10253 4/20 0.52
RAB9A P51151 3/20 0.52
KDM4E B2RXH2 3/20 0.52
CYP3A4 P08684 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
TAS2R38 P59533 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KDM4D Q6B0I6 1/20 0.47
KMT2A Q03164 4/20 0.45
HTT P42858 1/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6816258 0.88 MAPT (0.46) MAPTALDH1A1MAOAMAOBGAA
SCHEMBL6816248 0.83 ALDH1A1 (0.51) MAPTALDH1A1MAOAMAOBGAA
SCHEMBL8160305 0.83 MAPT (0.51) MAPTALDH1A1MAOAMAOBGAA
SCHEMBL6814946 0.83 MAPT (0.54) MAPTGAARAB9AKDM4ECYP2C9
SCHEMBL4325535 0.81 HSP90AA1 (0.50) MAPTALDH1A1MAOAMAOBRAB9A
SCHEMBL8168568 0.79 ALDH1A1 (0.47) MAPTALDH1A1MAOAMAOBGAA
SCHEMBL13343685 0.77 ALDH1A1 (0.45) MAPTALDH1A1RAB9AKDM4EKMT2A
SCHEMBL8155134 0.75 MAPT (0.53) MAPTALDH1A1GAARAB9AKDM4E
SCHEMBL4508668 0.74 MAPT (0.50) MAPTALDH1A1MAOAMAOBGAA
SCHEMBL29243709 0.74 ALDH1A1 (0.44) MAPTALDH1A1GAARAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656991-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2017-05-23 US disclosed
US-9656991-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2017-05-23 US disclosed
EP-2865670-B1 Thiourea derivatives as glutaminyl cyclase inhibitors PROBIODRUG AG (DE) 2017-01-11 EP disclosed
EP-2865670-A1 Thiourea derivatives as glutaminyl cyclase inhibitors Probiodrug AG (DE) 2015-04-29 EP disclosed
US-20080286231-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-11-20 US disclosed
US-20080286231-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-11-20 US disclosed
WO-2008128985-A1 THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS PROBIODRUG AG (DE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080286231-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, QPCT MAPT 730/4885ALDH1A1 1847/4885MAOA 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.